ADAM12, ADAM metallopeptidase domain 12, 8038

N. diseases: 107; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.400 GeneticVariation disease UNIPROT
CUI: C1321872
Disease: Stage IV Skin Melanoma
Stage IV Skin Melanoma 		0.300 GeneticVariation disease UNIPROT
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The expression of ADAM12 in cells cultured from the tumour was linked to the presence of multinucleated giant cells. 12456779 2002
CUI: C0017525
Disease: Giant Cell Tumors
Giant Cell Tumors 		0.010 Biomarker group BEFREE These results indicate that multinucleated giant cells are formed by the cell fusion of mononuclear stromal cells in giant cell tumours of bone and that ADAM12 is involved in the cell fusion process. 12456779 2002
CUI: C1839839
Disease: MAJOR AFFECTIVE DISORDER 2
MAJOR AFFECTIVE DISORDER 2 		0.010 Biomarker disease BEFREE ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice. 12414501 2002
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE In conclusion, in liver cancers ADAM9 and ADAM12 expression is associated with tumor aggressiveness and progression. 12717386 2003
CUI: C0086692
Disease: Benign Neoplasm
Benign Neoplasm 		0.020 AlteredExpression group BEFREE In vivo, the steady-state of both ADAM9 and ADAM12 mRNA levels was nearly undetectable in both normal livers and benign tumors and increased in hepatocellular carcinomas (up to 3- and 6-fold, respectively) and liver metastases from colonic carcinomas (up to 40- and 60-fold, respectively). 12717386 2003
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 AlteredExpression group BEFREE In vivo, the steady-state of both ADAM9 and ADAM12 mRNA levels was nearly undetectable in both normal livers and benign tumors and increased in hepatocellular carcinomas (up to 3- and 6-fold, respectively) and liver metastases from colonic carcinomas (up to 40- and 60-fold, respectively). 12717386 2003
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms 		0.010 AlteredExpression group LHGDN ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. 12717386 2003
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.010 AlteredExpression disease BEFREE ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. 12717386 2003
CUI: C0494165
Disease: Secondary malignant neoplasm of liver
Secondary malignant neoplasm of liver 		0.010 AlteredExpression disease BEFREE In vivo, the steady-state of both ADAM9 and ADAM12 mRNA levels was nearly undetectable in both normal livers and benign tumors and increased in hepatocellular carcinomas (up to 3- and 6-fold, respectively) and liver metastases from colonic carcinomas (up to 40- and 60-fold, respectively). 12717386 2003
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.090 AlteredExpression group LHGDN ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. 15381692 2004
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.020 AlteredExpression disease LHGDN These data demonstrate for the first time that among the 13 different ADAM species, ADAM12m is highly expressed in human glioblastomas, and suggest the possibility that ADAM12m plays a role in the prominent proliferation of the glioblastomas through shedding of heparin-binding epidermal growth factor. 15509542 2004
CUI: C0023890
Disease: Liver Cirrhosis
Liver Cirrhosis 		0.010 AlteredExpression disease LHGDN Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. 16139919 2005
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 Biomarker disease BEFREE The administration of anti-ADAM9 and anti-ADAM15 antibodies inhibited cell growth, whereas anti-ADAM12 enhanced the proliferation of the GC cell lines. 15586220 2005
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma 		0.010 Biomarker disease BEFREE The administration of anti-ADAM9 and anti-ADAM15 antibodies inhibited cell growth, whereas anti-ADAM12 enhanced the proliferation of the GC cell lines. 15586220 2005
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.060 AlteredExpression phenotype BEFREE Taken together, these results providing evidence for an overexpression of ADAM-12 and a lower expression of ADAMTS-1 in non-small-cell lung cancer suggest that these proteases play different functions in cancer progression. 16495931 2006
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms 		0.010 AlteredExpression group LHGDN Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). 16495931 2006
CUI: C0013080
Disease: Down Syndrome
Down Syndrome 		0.030 Biomarker disease BEFREE The maternal serum concentration of ADAM12 appears to be a very good marker of trisomy 21 in the early first trimester when levels are reduced, and in the second trimester around 16-18 weeks levels are elevated. 17701664 2007
CUI: C0013080
Disease: Down Syndrome
Down Syndrome 		0.030 Biomarker disease LHGDN Medians of normal pregnancies were established by polynomial regression and the distribution of log(10) MoM ADAM 12 values in DS pregnancies and controls determined. 17465398 2007
CUI: C0152096
Disease: Complete trisomy 18 syndrome
Complete trisomy 18 syndrome 		0.020 Biomarker disease BEFREE There was a significant correlation of ADAM12 MoM with gestational age (r = 0.510) in trisomy 18 cases, and the median MoM increased from 0.51 at 10 weeks to 1.28 at 13 weeks and 2.09 across the 14-18 week window. 17701664 2007
CUI: C4317091
Disease: Trisomy 18 Syndrome
Trisomy 18 Syndrome 		0.020 Biomarker disease BEFREE There was a significant correlation of ADAM12 MoM with gestational age (r = 0.510) in trisomy 18 cases, and the median MoM increased from 0.51 at 10 weeks to 1.28 at 13 weeks and 2.09 across the 14-18 week window. 17701664 2007
CUI: C0008626
Disease: Congenital chromosomal disease
Congenital chromosomal disease 		0.010 Biomarker group BEFREE ADAM12 may be a useful addition to early screening for trisomy 18 alongside other chromosomal anomalies, particularly if biochemical screening can occur before 10 weeks. 17701664 2007
CUI: C0028754
Disease: Obesity
Obesity 		0.010 GeneticVariation disease BEFREE We have identified two QTL genes, Adam12 and Cdh2, as causal genetic variants for atherogenic diet-induced obesity. 17653278 2007
CUI: C0494463
Disease: Alzheimer Disease, Late Onset
Alzheimer Disease, Late Onset 		0.010 GeneticVariation disease BEFREE Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. 17440933 2007